Physician profile
Jay S Umarvadia
NPI 1588906671
$5,057.90
in general payments reported to CMS, 2019-2025
10 companies · $298 in 2025
The $298 reported for 2025 was more than what 76% of Sports Medicine (Family Medicine) providers received nationally (typical 2025 total: $113).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $356 · 2020: $305 · 2021: $3,588 · 2022: $120 · 2023: $38.88 · 2024: $351 · 2025: $298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $688.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $688.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $3,614.30 | 2019-2022 | |
| Bioventus LLC | $451.96 | 2024-2025 | Durolane, Exogen Ultrasound Bone Healing System |
| Pacira Therapeutics, INC. | $370.04 | 2019-2021 | |
| Zimmer Biomet Holdings, INC. | $304.49 | 2019-2024 | Gel-One Cross-Linked Hyaluronate |
| Depuy Synthes Sales INC. | $105.65 | 2021-2024 | Monovisc, Orthovisc |
| Sanofi-Aventis U.S. LLC | $77.38 | 2019-2023 | |
| Prime Surgical, LLC | $65.82 | 2024 | |
| Djo, LLC | $35.11 | 2024 | Cmf |
| Kowa Pharmaceuticals America, INC. | $20.40 | 2022 | |
| Heron Therapeutics, INC. | $12.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Umarvadia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.